Pfizer raised its full-year sales and adjusted earnings outlook on 3 November, despite an 8% decline in reported third-quarter net income. The results show growth outside COVID-19 products offsetting pressure elsewhere in the business, while different profit measures tell different stories.
Quarterly revenue was US$16.583 billion, compared with US$16.654 billion a year earlier — effectively flat. Net income attributable to common shareholders fell to US$3.242 billion from US$3.541 billion. Reported diluted earnings per share declined from 62 to 56 cents.
Adjusted income, which excludes specified items, rose 1% to US$4.985 billion, and adjusted earnings per share were unchanged at 87 cents. The decline in the reported figure therefore should not be presented as a fall in every measure of operating performance.
Excluding Comirnaty and Paxlovid, sales grew 7% on an operational basis, which removes currency effects. Newly launched and acquired products grew 32% by that measure. Those are defined parts of the portfolio, not growth rates for Pfizer’s total revenue.
The company now expects annual revenue of US$62 billion to US$64 billion, up from US$60.5 billion to US$62.5 billion. It also raised and narrowed adjusted earnings guidance to US$2.95–US$3.05 per share. Research and development spending increased as the group continued work across oncology, obesity and other areas.
The commercial challenge remains replacing fading pandemic-era demand with durable sales from the wider portfolio. Higher guidance is management’s forecast, not a completed annual result. Future trial milestones and product launches also remain separate from the financial performance already reported.
